## **Table of Contents** 1. [The Central Tension: Profits Without Cash](#anchor1) 2. [Business Model and Operational Reality](#anchor2) 3. [Financial Quality: Where the Numbers Tell a Different Story](#anchor3) 4. [Working Capital: The Growing Burden](#anchor4) 5. [IPO Proceeds: Funding Growth or Plugging Holes](#anchor5) 6. [Promoter Economics and Governance Red Flags](#anchor6) 7. [The Bottom Line](#anchor7) --- <h2 id="anchor1">The Central Tension: Profits Without Cash</h2> Harikanta Overseas Limited reported PAT of ₹508.58 lakh for eight months ended November 2025, yet generated negative operating cash flow of ₹14.81 lakh. For FY2025, the company posted PAT of ₹446.80 lakh while burning ₹43.17 lakh in operating cash flow. **This is not a profitable business — it reports earnings it has not collected.** The textile manufacturer seeks to raise ₹26 crore through SME IPO on BSE Limited's SME Platform, with price band ₹91-96 per share, opening May 20, 2026. The company specializes in synthetic textile fabrics, particularly Ikat fabrics for women's wear. Beneath impressive margin expansion lies troubling cash flow deterioration that new investors are being asked to fund. <h2 id="anchor2">Business Model and Operational Reality</h2> Harikanta operates in textile manufacturing, producing synthetic fabrics focused on women's wear. Revenue grew from ₹1,490.27 lakh in FY2023 to ₹3,517.30 lakh in FY2025, while EBITDA margins expanded from 3.23% to 18.92%. The company maintains clean regulatory record with no pending litigation. **The business model reveals structural weaknesses.** Trade receivables surged from ₹400.08 lakh in March 2025 to ₹1,311.30 lakh by November 2025. This massive working capital absorption coincides with reported profit growth, suggesting earnings accumulate as receivables rather than converting to cash. Working capital efficiency deteriorated dramatically. Inventory turnover fell from 7.25 times in March 2025 to 2.04 times by November 2025. Trade receivables turnover declined from 13.21 times to 3.05 times. Trade payables turnover dropped from 7.73 times to 1.93 times. This simultaneous deterioration indicates aggressive revenue recognition or fundamental collection problems. <h2 id="anchor3">Financial Quality: Where the Numbers Tell a Different Story</h2> PAT margins expanded from 1.69% in FY2023 to 12.70% in FY2025, reaching 19.35% by November 2025. EBITDA margins improved from 3.23% to 18.92% and then 27.97%. However, these improvements coincide with dramatic cash flow deterioration. **Operating cash flow was negative ₹43.17 lakh in FY2025 despite PAT of ₹446.80 lakh.** For eight months ended November 2025, operating cash flow remained negative ₹14.81 lakh while PAT was ₹508.58 lakh. This pattern indicates revenue recognition on work customers haven't paid for. Trade receivables increased from ₹132.25 lakh in March 2024 to ₹400.08 lakh in March 2025, exploding to ₹1,311.30 lakh by November 2025. Finished goods inventory grew from ₹19.41 lakh to ₹434.02 lakh, moderating to ₹279.77 lakh by November 2025. Total borrowings declined from ₹147.33 lakh in March 2024 to ₹8.66 lakh by November 2025. Debt-equity ratio fell from 0.75 to 0.15. However, this improvement reflects equity expansion rather than cash generation. <h2 id="anchor4">Working Capital: The Growing Burden</h2> Net working capital increased from negative ₹30.25 lakh in March 2024 to ₹694.52 lakh in March 2025, reaching ₹1,187.88 lakh by November 2025. **This massive cash absorption explains negative operating cash flows despite reported profits.** Trade receivables of ₹400.08 lakh in March 2025 comprised ₹360.70 lakh (95.38%) aged less than one year. By November 2025, total receivables surged to ₹1,311.30 lakh, indicating expanded credit terms or collection difficulties. The company projects working capital requirements of ₹850 lakh in FY2026 and ₹1,125 lakh in FY2027, with ₹475 lakh from IPO proceeds. These projections assume improved efficiency, yet every metric has deteriorated. <h2 id="anchor5">IPO Proceeds: Funding Growth or Plugging Holes</h2> The IPO raises ₹26 crore through 2,670,000 shares at ₹91-96. Proceeds fund factory premises (₹540.35 lakh), machinery (₹932.50 lakh), working capital (₹475 lakh), and general purposes. **The machinery component represents growth.** Plans include 20 rapier looms, 10 air-jet looms, and 8 shuttleless looms to increase capacity to 14,48,400 meters. Commercial production targets FY2026-27. **Working capital funding appears insufficient.** The company allocates ₹475 lakh for working capital in FY2027, yet net working capital already reached ₹1,187.88 lakh by November 2025. With deteriorating efficiency, projected funding may prove inadequate. <h2 id="anchor6">Promoter Economics and Governance Red Flags</h2> Three promoters hold 69,70,740 shares pre-IPO . **The company issued 59,74,920 bonus shares to Abhishek, Hardik, and Nilesh Gotawala* Related party transactions include ₹95.84 lakh purchases from Abhishek Tex Feb (director's firm), ₹35.53 lakh jobwork charges, and ₹83.65 lakh unsecured loan from Shree Jalaram Enterprise. <h2 id="anchor7">The Bottom Line</h2> Harikanta Overseas reported PAT of ₹508.58 lakh while generating negative operating cash flow of ₹14.81 lakh — **a company growing its balance sheet faster than its bank account.** Trade receivables surge from ₹400.08 lakh to ₹1,311.30 lakh, combined with deteriorating working capital efficiency, creates questionable cash conversion. Genuine strengths — revenue growth to ₹3,517.30 lakh, EBITDA margin expansion to 18.92%, clean regulatory record — are overshadowed by fundamental cash generation problems. Competing promoter businesses, substantial related party transactions, and aggressive projections despite deteriorating efficiency suggest investors fund expansion of unproven cash conversion capability. Before investing, demand clarity on cash collection timelines, customer payment terms, and binding agreements restricting promoter competition. **This business must prove it can collect reported profits before seeking growth capital.** **Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice. Investors should conduct due diligence and consult qualified financial advisors. Past performance does not guarantee future results, and all investments carry risk of loss.